Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.90 --0%
EPS Growth %: -30.4%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -30.4%
Financial Fact:
Total operating expenses: 39.14M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $64.5 million versus the consensus estimate of $67.6 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- BAE Systems Plc (BA:LN) (BAESY) New Top Pick in EU Defence at Morgan Stanley
- Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
